
NBD-11021
CAS No. 1427304-84-4
NBD-11021( NBD11021 )
Catalog No. M11804 CAS No. 1427304-84-4
A small molecule, full antagonist of CD4 that blocks gp120-CD4 interaction.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameNBD-11021
-
NoteResearch use only, not for human use.
-
Brief DescriptionA small molecule, full antagonist of CD4 that blocks gp120-CD4 interaction.
-
DescriptionA small molecule, full antagonist of CD4 that blocks gp120-CD4 interaction; inhibits the CD4-dependent virus in a dose-dependent manner with IC50 of 2.4 uM; also weakly shows HIV-1 RT inhibition with IC50 of 43.4 uM; exhibits pan-neutralization activity against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clinical isolates (IC50 as low as 270 nM).HIV Preclinical.
-
In Vitro——
-
In Vivo——
-
SynonymsNBD11021
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1427304-84-4
-
Formula Weight444.978
-
Molecular FormulaC22H25ClN4O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name5-(4-chlorophenyl)-N-((5-(hydroxymethyl)-4-methylthiazol-2-yl)(piperidin-2-yl)methyl)-1H-pyrrole-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Curreli F, et al. J Med Chem. 2015 Sep 10;58(17):6909-6927.
molnova catalog



related products
-
HIV-1 Nef-IN-1
HIV-1 Nef-IN-1 is an inhibitor of HIV-1 Nef protein. It efficiently competes for Nef-SH3Hck interactions(Kd : 6.7 μM).
-
Bevirimat
Bevirimat(PA-457) is a first-in-class inhibitor of HIV-1 maturation blocking the cleavage of the Gag capsid (CA) precursor CA-SPI to mature CA protein during virion maturation.
-
BNM-III-170 trifluor...
BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.